Market Data 
Markets
Replies to post #177928 on Biotech Values
09/09/14 9:13 AM
MabVax Therapeutics Holdings, Inc., a publicly-traded clinical stage cancer immunotherapy company, announced today that stockholders have approved a change in the Company's name from Telik, Inc. to MabVax Therapeutics Holdings Inc., as well as a change in ticker symbol to MBVX that will likely take effect within the next three weeks.
Stockholders also approved a reverse stock split at a ratio in the range of 1:5 to 1:15 and the authorization of additional common and preferred shares. These actions mark the completion of the actions that were originally intended to take effect at the time of the July 8, 2014 merger between MabVax and Telik. More than 70% of all outstanding shares voted in favor of all proposals in the proxy which was sent out on or about July 30, 2014.
AI
